Browse the corpus

REFERENCES Allen LV and Erickson MA 3d, “Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,” Am J Health Syst Pharm , 1996, 53(16):1944-9. [PubMed 8862208 ] American Academy of Pediatrics Committee on Drugs, "Transfer of Drugs and Other Chemicals Into Human Milk," Pediatrics , 2001, 108(3):776-89. [PubMed 11533352 ] Appelbaum SJ, Mayersohn M, Dorr RT, et al, “Allopurinol Kinetics and Bioavailability. Intravenous, Oral and Rectal Administration,” Cancer Chemother Pharmacol , 1982, 8(1):93-8. [PubMed 7094203 ] Coiffier B, Altman A, Pui CH, et al, “Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review,” J Clin Oncol , 2008, 26(16):2767-78. [PubMed 18509186 ] Dalbeth N and Stamp L, “Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events,” Semin Dial , 2007, 20(5):391-5. [PubMed 17897242 ] Day RO, Graham GG, Hicks M, et al, “Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol,” Clin Pharmacokinet , 2007, 46(8):623-44. Elasy T, Kaminsky D, Tracy M, et al, “Allopurinol Hypersensitivity Syndrome Revisited,” West J Med , 1995, 162(4):360-1. [PubMed 7747507 ] El-Zawawy H and Mandell BF, “Managing Gout: How is it Different in Patients With Chronic Kidney Disease?” Cleve Clin J Med , 2010, 77(12):919-28. Emmerson BT, “The Management of Gout,” N Engl J Med , 1996, 334(7):445-51. [PubMed 8552148 ] Fravel MA and Ernst ME, “Management of Gout in the Older Adult,” Am J Geriatr Pharmacother , 2011, 9(5):271-85. [PubMed 21849262 ] Gahart BL and Nazareno AR, 2012 Intravenous Medications: A Handbook for Nurses and Health Professionals , 28th ed, St Louis, MO: Elsevier/Mosby, 2012, 58-9. Hande KR, Noone RM, and Stone WJ, “Severe Allopurinol Toxicity,” Am J Med , 1984, 76(1):47-56. [PubMed 6691361 ] McGill NW, “Management of Gout: Beyond Allopurinol,” Int Med J , 2010, 40(8):545-53. [PubMed 20561096 ] Murrell GA and Rapeport WG, “Clinical Pharmacokinetics of Allopurinol,” Clin Pharmacokinet , 1986, 11(5):343-53. [PubMed 3536254 ] Parra E, Gota R, Gamen A, et al, “Granulomatous Interstitial Nephritis Secondary to Allopurinol Treatment,” Clin Nephrol , 1995, 43(5):350. [PubMed 7634557 ]

McGill NW, “Management of Gout: Beyond Allopurinol,” Int Med J , 2010, 40(8):545-53. [PubMed 20561096 ] Murrell GA and Rapeport WG, “Clinical Pharmacokinetics of Allopurinol,” Clin Pharmacokinet , 1986, 11(5):343-53. [PubMed 3536254 ] Parra E, Gota R, Gamen A, et al, “Granulomatous Interstitial Nephritis Secondary to Allopurinol Treatment,” Clin Nephrol , 1995, 43(5):350. [PubMed 7634557 ] Stamp LK, O’Donnell JL, Zhang M, et al, “Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic gout, Including Those With Renal Impairment,” Arthritis Rheum , 2011, 63(2):412-21. [PubMed 21279998 ] Zhang W, Doherty M, Bardin T, et al, “EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Ann Rheum Dis , 2006, 65(10):1312-24. [PubMed 16707532 ] Topic 8439 Version 43.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]